Davis Investment Partners LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 5,006 shares of the biopharmaceutical company's stock, valued at approximately $533,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC grew its holdings in Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after buying an additional 7,157,113 shares during the last quarter. Wellington Management Group LLP grew its holdings in Gilead Sciences by 3.1% in the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock valued at $3,293,822,000 after buying an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC grew its holdings in Gilead Sciences by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock valued at $2,608,337,000 after buying an additional 749,047 shares during the last quarter. Norges Bank acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $1,789,254,000. Finally, Northern Trust Corp grew its holdings in shares of Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after purchasing an additional 2,458,954 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences Stock Performance
Shares of NASDAQ GILD traded up $2.75 during trading hours on Thursday, reaching $112.05. 7,023,598 shares of the stock were exchanged, compared to its average volume of 7,745,911. The firm has a market capitalization of $139.38 billion, a price-to-earnings ratio of 302.84, a P/E/G ratio of 0.71 and a beta of 0.29. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a 52 week low of $62.69 and a 52 week high of $119.96. The stock's fifty day simple moving average is $105.40 and its 200 day simple moving average is $101.91.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm's quarterly revenue was down .3% compared to the same quarter last year. During the same quarter last year, the company earned ($1.32) earnings per share. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.82%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.
Insider Buying and Selling
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total value of $249,550.00. Following the sale, the chief financial officer now owns 165,674 shares of the company's stock, valued at approximately $16,537,578.68. This trade represents a 1.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the sale, the chief executive officer now directly owns 620,268 shares in the company, valued at approximately $68,489,992.56. This represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,000 shares of company stock valued at $4,630,310 over the last 90 days. 0.27% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Several analysts recently commented on GILD shares. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a research note on Thursday, February 13th. The Goldman Sachs Group boosted their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Cantor Fitzgerald began coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective for the company. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and boosted their target price for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Finally, Morgan Stanley boosted their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $110.55.
Check Out Our Latest Analysis on GILD
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Stories
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
